Novartis takes a $200M hit to write off a flop as execs spell out a cautious R&D strategy
With its top line locked into a holding pattern as its sales teams struggle to expand franchise revenue, Novartis has outlined its near-term R&D strategy …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
